PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma

Table 3 Case description of PIK3CA-mutant glioblastomas

Case	Age	Sex	Tumor at presentation	Type of surgery	KPS	PIK3CA mutation	MGMT	IDH1	EGFR	Other alterations	PFS (mo.)	OS (mo.)
1	67	M	multicentric	PR	90	H1047R	u	wt	n.t.	TP53 R248W	6.3	9.7
2	68	M	gliomatosis	biopsy	90	R88Q	n.t.	wt	N		3.2	5.1
3	31	M	leptomeningeal metastasis	biopsy	90	H1047R	n.t.	wt	N		6.6	10.9
4	42	F	single lesion	PR	100	R88Q	m	wt	N	TP53 R273C	12.4	54.9
5	72	F	single lesion	GTR	90	R88Q	m	wt	N		5.3	10.6
6	35	F	multicentric	GTR	90	Q546R	u	wt	amp		26.6	32.4
7	25	M	multicentric	biopsy	80	R88Q	m	wt	N		6.9	19.1
8	65	F	single lesion	GTR	100	Q546K	m	wt	N		7.6	36.9
9	43	M	single lesion	PR	90	E545K	u	wt	N		5.7	11
10	32	M	single lesion	PR	100	H1047R	m	wt	N		13.8	17.7*
11	54	M	single lesion	GTR	100	E542K	m	wt	N		34.8*	34.8*
12	57	M	gliomatosis	biopsy	80	H1047Y	m	wt	N		6.6	21.2
13	51	M	single lesion	GTR	100	H1047R	m	wt	amp		14.9	31.1

Abbreviations: M, male; F, female; PR, partial resection; GTR, gross total resection; KPS, Karnofsky performance status; n.t., not tested; IDH1, isocitrate dehydrogenase 1; MGMT, O⁶-methylguanine-DNA methyltransferase promoter methylation; m, methylated; u, unmethylated; wt, wild-type; amp, amplified; N, non-amplified; PFS, progression-free survival; OS, overall survival; mo., months; *censored at last follow-up

ISSN: 2051-5960